We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Fig 3

Fig 3. From: Recombinant Parainfluenza Virus 5 Vaccine Encoding the Influenza Virus Hemagglutinin Protects against H5N1 Highly Pathogenic Avian Influenza Virus Infection following Intranasal or Intramuscular Vaccination of BALB/c Mice.

Immunization with live rPIV5-H5 protects against HPAI challenge. BALB/c mice were immunized i.n. or i.m. with PIV5, rPIV5-H5 (ZL46), inactivated rPIV5-H5 (iZL46), iZL46 i.m., a sublethal dose of rgA/VN-PR8 i.n., or rgA/VN-PR8 i.m. Twenty-eight days p.i., the mice were challenged i.n. with 10 LD50 A/VN/1203/04. (A) Weights of the mice were monitored and are presented as the mean percentages ± SEM of their prechallenge body weights (n = 8). (B) Survival rate of mice. (C) Virus titer in the lungs on day 3 postchallenge (n = 5 per group) as measured by TCID50.

Alaina J. Mooney, et al. J Virol. 2013 January;87(1):363-371.
2.
Fig 4

Fig 4. From: Recombinant Parainfluenza Virus 5 Vaccine Encoding the Influenza Virus Hemagglutinin Protects against H5N1 Highly Pathogenic Avian Influenza Virus Infection following Intranasal or Intramuscular Vaccination of BALB/c Mice.

Boosting with rPIV5-H5 enhances HA-specific antibody responses. BALB/c mice (n = 5 per group) were immunized with PIV5 i.n., ZL46 i.n. or i.m., iZL46 i.m., or iA/VN/1203/04 i.m. Mice were bled on days 7, 14, and 21 p.i. On day 28 p.i., mice were boosted as described in the text, and serum was collected on days 7 and 14 postboost. Serum was pooled for analysis. (A) HA (H5) specific antibody titers were measured in serum samples using an IgG-specific ELISA. The dotted line represents the limit of detection. (B) rgA/VN-PR8-neutralizing antibody titers in postimmunization serum. (C) Mice were challenged with rgA/VN-PR8, and virus titers in the lungs were measured on day 3 postchallenge (n = 5 per group) by TCID50.

Alaina J. Mooney, et al. J Virol. 2013 January;87(1):363-371.
3.
Fig 1

Fig 1. From: Recombinant Parainfluenza Virus 5 Vaccine Encoding the Influenza Virus Hemagglutinin Protects against H5N1 Highly Pathogenic Avian Influenza Virus Infection following Intranasal or Intramuscular Vaccination of BALB/c Mice.

rPIV5-H5 incorporates HA into the virion and expresses H5 during infection. (A) Cartoon showing the genome of ZL48 and ZL48, indicating the location of the H5 HA gene insertion. (B) MDBK cells were infected with PIV5, ZL48, or ZL46 (MOI, 0.1) for 72 h, and supernatants were collected, purified, and separated on SDS-PAGE gel and imaged by Coomassie blue staining. (C) MDBK cells infected with PIV5, ZL48, or ZL46 (MOI, 5) were lysed 24 h later, separated by SDS-PAGE, transferred to PVDF, and blotted with a monoclonal antibody specific to the V/P proteins of PIV5 and hyperimmune serum from mice infected with rgA/VN-PR8 to detect HA. (D) Vero cells were infected with PIV5 or ZL46 or were mock infected. At 24 h p.i., cells were fixed and stained with anti-H5 (red) and anti-V/P (green) monoclonal antibodies. Immunofluorescent micrographs were taken at ×20 magnification (bar, 200 μm).

Alaina J. Mooney, et al. J Virol. 2013 January;87(1):363-371.
4.
Fig 2

Fig 2. From: Recombinant Parainfluenza Virus 5 Vaccine Encoding the Influenza Virus Hemagglutinin Protects against H5N1 Highly Pathogenic Avian Influenza Virus Infection following Intranasal or Intramuscular Vaccination of BALB/c Mice.

Immunization with live rPIV5-H5 induces HA-specific immune responses. BALB/c mice (n = 5 per group) were immunized with PIV5 i.n., ZL46 i.n. or i.m., iZL46 i.m., or iA/VN/1203/04 i.m. Mice were bled on days 7, 14, and 21 p.i. Serum was pooled for analysis. (A) HA (H5)-specific antibody titers were measured in serum samples using an IgG-specific ELISA. The dotted line represents the limit of detection. (B) rgA/VN-PR8-neutralizing antibody titers in p.i. serum. Mice were immunized i.n. or i.m. with PIV5, ZL46, or a sublethal dose of rgA/VN-PR8, and nasal wash (C) and BAL fluid (D) examinations were performed on days 14 or 21 p.i. Samples were pooled for analysis by HA-specific IgA ELISA. (E) IFN-γ-producing lymphocytes (pools of n = 3 mice per group) in the mediastinal lymph nodes on day 12 postvaccination as determined by ELISpot analysis. Data are presented as means ± standard errors of the means (SEM). Irrelev, irrelevant peptide.

Alaina J. Mooney, et al. J Virol. 2013 January;87(1):363-371.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk